Literature DB >> 31345843

Managing All the Genotypic Knowledge: Approach to a Septic Patient Colonized by Different Enterobacteriales with Unique Carbapenemases.

Stacy C Park1, Alexander M Wailan2, Katie E Barry2, Kasi Vegesana3, Joanne Carroll4, Amy J Mathers1,4, William R Miller5,6, Jose M Munita7,6,8,9.   

Abstract

The recent development of new antimicrobials active against carbapenemase-producing Enterobacteriales (CPE) has brought new hope for the treatment of infections due to these organisms. However, the evolving epidemiology of bacteria with carbapenemases may complicate management, as providers are faced with treating patients colonized by bacteria producing multiple carbapenemases. Here, we present the clinical course and treatment of Raoultella planticola bacteremia in a cirrhotic patient known to be colonized with both bla KPC- and bla OXA-48-carrying organisms.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  OXA-48; Raoultella planticolazzm321990; carbapenem-resistant Enterobacteriales (CRE); carbapenemase-producing Enterobacteriales (CPE); ceftazidime-avibactam

Mesh:

Substances:

Year:  2019        PMID: 31345843      PMCID: PMC6658741          DOI: 10.1128/AAC.00029-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

2.  First report of an OXA-48-producing multidrug-resistant Proteus mirabilis strain from Gaza, Palestine.

Authors:  Liang Chen; Nahed Al Laham; Kalyan D Chavda; Jose R Mediavilla; Michael R Jacobs; Robert A Bonomo; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

3.  Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.

Authors:  Cristina De la Calle; Olga Rodríguez; Laura Morata; Francesc Marco; Celia Cardozo; Carolina García-Vidal; Ana Del Río; Csaba Feher; Martina Pellicé; Pedro Puerta-Alcalde; Josep Mensa; Alex Soriano; Jose Antonio Martínez
Journal:  Int J Antimicrob Agents       Date:  2018-11-22       Impact factor: 5.283

Review 4.  Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.

Authors:  Jason M Pogue; Robert A Bonomo; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2019-01-18       Impact factor: 9.079

5.  Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study.

Authors:  Anthony D Bai; Adrienne Showler; Lisa Burry; Marilyn Steinberg; Daniel R Ricciuto; Tania Fernandes; Anna Chiu; Sumit Raybardhan; Michelle Science; Eshan Fernando; George Tomlinson; Chaim M Bell; Andrew M Morris
Journal:  Clin Infect Dis       Date:  2015-02-20       Impact factor: 9.079

6.  Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae.

Authors:  Virginia M Pierce; Patricia J Simner; David R Lonsway; Darcie E Roe-Carpenter; J Kristie Johnson; William B Brasso; April M Bobenchik; Zabrina C Lockett; Angella Charnot-Katsikas; Mary Jane Ferraro; Richard B Thomson; Stephen G Jenkins; Brandi M Limbago; Sanchita Das
Journal:  J Clin Microbiol       Date:  2017-04-05       Impact factor: 5.948

Review 7.  Treatment of Infections by OXA-48-Producing Enterobacteriaceae.

Authors:  Adam Stewart; Patrick Harris; Andrew Henderson; David Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 8.  Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat.

Authors:  Yamuna Devi Bakthavatchalam; Shalini Anandan; Balaji Veeraraghavan
Journal:  J Glob Infect Dis       Date:  2016 Jan-Mar

9.  Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections.

Authors:  Jason P Burnham; Margaret A Olsen; Dustin Stwalley; Jennie H Kwon; Hilary M Babcock; Marin H Kollef
Journal:  Open Forum Infect Dis       Date:  2018-03-15       Impact factor: 3.835

10.  Phenotypic and Genotypic Characterization of Enterobacteriaceae Producing Oxacillinase-48-Like Carbapenemases, United States.

Authors:  Joseph D Lutgring; Wenming Zhu; Tom J B de Man; Johannetsy J Avillan; Karen F Anderson; David R Lonsway; Lori A Rowe; Dhwani Batra; J Kamile Rasheed; Brandi M Limbago
Journal:  Emerg Infect Dis       Date:  2018-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.